

Specialty R&D Pipeline

Phase 2	Phase 3	Registration	Approved in 2017	
Funapide (TV-45070, Nav1.7) <i>Neuropathic pain</i>	Fremanezumab (anti CGRP) <i>Chronic migraine (Global)</i>	Austedo® <i>Tardive dyskinesia (U.S.)</i>	Vantrela® ER <i>Pain (U.S.)</i>	<p>16 programs in phase 2 through Submission, 24 products in phase 1 or planned IND by 2019</p> <ul style="list-style-type: none"> ■ Migraine & Pain 6 ■ Neurology & neuropsychiatry 5 ■ Respiratory 2 ■ Biosimilars 2 ■ Other TA 1
Fasinumab ** <i>Chronic Lower Back Pain</i>	Fremanezumab (anti CGRP) <i>Episodic migraine (Global)</i>	Azilect® <i>Parkinson's disease (Japan)****</i>	Austedo® <i>Huntington Disease (U.S.)</i>	
Laquinimod <i>Multiple sclerosis (primary progressive)</i>	Fremanezumab (anti CGRP) <i>Cluster Headache (Global)</i>	Reslizumab* IV <i>Asthma (Growth Markets)</i>	ArmonAir® RespiClick® <i>Asthma (U.S.)</i>	
Laquinimod <i>Huntington disease</i>	Fasinumab ** <i>Osteoarthritis pain (Global)</i>	CT-P10 *** <i>Biosimilar (Rituxan® U.S.)</i>	AirDuo® RespiClick® <i>Asthma (U.S.)</i>	
Pridopidine <i>Huntington disease</i>	Reslizumab* SC <i>Asthma (Global)</i>	CT-P6 *** <i>Biosimilar (Herceptin® U.S.)</i>	QVAR® (beclomethasone dipropionate BAI) <i>Asthma (U.S.)</i>	
		BENDEKA® ***** <i>CLL and NHL (Growth Markets)</i>		

Note: Pipeline is current as of Aug 7, 2017.

* Approved in the U.S. under the trade name: CINQAIR® **In partnership with Regeneron *** In partnership with Celltrion

**** Submitted by Takeda ***** In partnership with Eagle Pharmaceuticals